Physician profile
Aneesh Singla
NPI 1205826377
$167,282.06
in general payments reported to CMS, 2019-2025
42 companies · $1,501 in 2025
The $1,501 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,260 · 2020: $291 · 2021: $333 · 2022: $159K · 2023: $2,385 · 2024: $2,209 · 2025: $1,501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,945 · Travel and Lodging: $1,134 · Education: $15.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,945.30 |
| Travel and Lodging | $1,133.83 |
| Education | $15.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Curonix LLC | $157,535.08 | 2022-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Abbott Laboratories | $1,716.57 | 2019-2025 | Proclaim, Eterna, Prodigy |
| Medtronic, INC. | $1,711.12 | 2022-2025 | Intellis Adaptivestim, Synchromedii, Kyphon Express II Kyphopak Tray |
| Boston Scientific Corporation | $1,204.88 | 2019-2025 | Wavewriter Alpha Prime 16, Infinion 16, Intracept |
| Stryker Corporation | $1,059.40 | 2024 | Optablate, Spinejack, Mild Device Kit |
| Collegium Pharmaceutical, INC. | $606.09 | 2019-2024 | Xtampza, Belbuca |
| Vertos Medical, INC. | $380.16 | 2022-2024 | Mild Device Kit |
| Nevro Corp. | $377.25 | 2019-2024 | Senza |
| Relievant Medsystems, INC. | $340.00 | 2022-2023 | Intracept |
| Spinal Simplicity, LLC | $305.83 | 2022 | |
| Medtronic USA, INC. | $228.04 | 2019 | |
| Pfizer INC. | $160.21 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.00 | 2019-2023 | Relistor |
| Globus Medical, INC. | $145.91 | 2025 | Senza, Vyrsa V1 |
| Stimwave Technologies Incorporated | $144.67 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$52,294.25 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aneesh Singla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.